Purpose: vigiRank is a data-driven predictive model for emerging safety signals. In addition to disproportionate reporting patterns, it also accounts for the completeness, recency, and geographic spread of individual case reporting, as well as the availability of case narratives.
disproportionality analysis 2 is the state-of-the-art approach to statistical signal detection for pharmacovigilance, despite being based entirely on statistical associations, disregarding the strength of individual reports. This is clearly contrasted by manual clinical assessment, which carefully considers report quality 3 and attempts to account for all relevant aspects of the reported information. 4 In the hope of improving statistical signal detection performance, we recently devised a fundamentally different approach called vigiRank. 5 vigiRank is a data-driven predictive model for emerging safety signals that accounts for the completeness and recency of individual reports and their geographic diversity, alongside disproportional reporting and presence of narratives 5 (see Figure 1 ). Other approaches that combine disproportionality with orthogonal information in a similar manner have followed. 10 Retrospective evaluation against a set of historical safety signals from the European Medicines Agency indicated substantial improvement in signal detection performance with vigiRank compared to disproportionality analysis alone. 5 Such evaluation is more relevant than the standard practice of evaluating performance with labelled adverse drug reactions (ADRs) as positive controls. 11 However, until now, vigiRank's impact on prospective real-world pharmacovigilance has not been known.
In 2014, vigiRank was adopted as the core statistical signal detection method for the Uppsala Monitoring Centre's (UMC's) analysis of VigiBase, and we are now in a position to evaluate its performance in guiding prospective signal detection compared to that observed historically for disproportionality analysis. 
| DISCUSSION
This study provides empirical support that vigiRank, a recently devised method that simultaneously accounts for multiple strength-ofevidence aspects, offers higher real-world signal detection performance than disproportionality analysis alone. This corroborates our earlier retrospective evaluation 5 and lends support to the UMC's shift towards using vigiRank rather than disproportionality analysis as the basis for routine signal detection.
The main strengths of our study are its prospective nature for the vigiRank cohort, its overall size, and its independence of the data used for the development of vigiRank. Its main limitation is that there are Although vigiRank offers great improvement overall compared to disproportionality analysis, it does not generate a higher rate of initial assessments being sent for in-depth assessment by clinical experts. A possible explanation is that vigiRank proposes a set of drug-ADR pairs for initial assessment that are of generally superior quality and so subconsciously raises the bar for what is going to be subjected to in-depth assessment. The much more thorough and therefore labour-intensive approach of the in-depth assessments may be a contributing factor for such behaviour. Nevertheless, we are confident that it is the overall efficiency that is of real importance and the one that therefore should be measured. 13 It is important to note that our comparison does not contrast the vigiRank score and IC measure in isolation but reflects specific applications for practical use. For the IC, we highlighted drug-ADR pairs for which IC 025 exceeded 0 for the first time. For vigiRank, we reviewed pairs in the order of descending scores. This could explain part of the substantial gain in performance, which exceeds that observed in the previous retrospective comparison. 5 While the lowest observed vigiRank score among our assessed drug-ADR pairs (0.061) may appear low, it is clearly higher than the vigiRank score corresponding to presence of only disproportionality (see Figure 1) . Furthermore, in VigiBase globally, a vast majority of reported drug-ADR pairs have lower vigiRank scores than this.
vigiRank is different from the majority of other efforts to advance statistical signal detection in pharmacovigilance. Most developments seem to have been made in the area of multivariate methods aiming to account for possible confounders, such as age or indication for use, to adjust and generalise the crude reporting associations offered by disproportionality analysis. 14, 15 As noted elsewhere, this is orthogonal to the principles of vigiRank, and possible synergies might therefore be possible.
5
A challenge with a more complex method like vigiRank compared to basic disproportionality analysis is that it becomes more difficult to apply in other data sets. Adaptation could be made at different levels, where refitting the underlying predictive model in the target database is the most ambitious and most likely to succeed. 5 Also, whereas the vigiRank score itself may be opaque and not meaningful in clinical assessment, its individual components might. Specifically, disproportionality and geographic spread are aspects of strength of evidence in their own right.
In conclusion, combining multiple strength-of-evidence aspects as in vigiRank significantly outperforms disproportionality analysis alone in real-world pharmacovigilance signal detection, for VigiBase. This is a first success story in need of independent verification, but the substantial improvement observed warrants careful consideration by anyone seeking to improve their statistical signal detection for individual case reports.
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